BBC Recording: The Evidence (BBC Radio)

I attended the live recording of The Evidence for BBC Radio, hosted by Claudia Hammond. The focus: the future of weight loss medications like Ozempic and Wegovy — and what they mean for healthcare systems and society.

The conversation brought together leading experts from UCL, Oxford, Cambridge, and clinical practice, and it left me with a few big reflections:

• Obesity as a chronic disease. We are finally beginning to acknowledge obesity not as an individual failing, but as a chronic condition requiring systemic solutions. This shift in framing is as important as the medicines themselves.
• Medical breakthroughs with ripple effects. GLP-1 and GIP therapies are not just about weight loss (~15% reduction on average). They are showing real impact on type 2 diabetes, cardiovascular health, and potentially more — marking the end of the beginning for a new era in metabolic health.
• Equity and access. At ~$1,000 per month, these drugs raise urgent questions: how do we integrate them into public health systems? How do welfare programs and insurers adapt? Who gets left behind if we don’t?
• Beyond the pill/injection. Medicines can support, but they cannot replace prevention. Processed food environments, aggressive marketing, and supermarket design are all nudging societies toward overconsumption. Unless we redesign these systems, treatment will always be chasing the problem.

“This is not the end — it is the end of the beginning.”

The weight loss injection story is not just about medicine. It is about rethinking how health systems balance innovation with prevention, and how societies decide who gets access to life-changing interventions.

Thank you Claudia Hammond for curating such a rich discussion, and to the panel — Dr’s Adrian Brown, Giles Yeo, John Wilding, Barbara McGowan — for your expertise and candour.

The episode will air on BBC World Service on 18th October — well worth listening to.